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1. Introduction
Hepatocellular carcinoma (HCC) is the most frequent malignant tumor of the liver with hun-
dreds of thousands of new cases diagnosed each year. Men are up to 3 times more likely to 
develop HCC compared to women. HCC encounters a higher incidence in countries with low 
socio-economic status and with improper access to healthcare. These countries also associ-
ate high alcohol intake among the population as well as increased incidence of hepatotropic 
viruses or human immunodeficiency virus (HIV). On the other hand, screening and surveil-
lance of patients at risk have determined the upturn of survivability in HCC patients.
2. Risk factors
HCC has several well-known risk factors, which have been proven to strongly associate with 
the development of HCC. The most common etiological risk factors are hepatotropic viruses: 
hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) and a sugges-
tive evidence is revealed by similar distribution of HCC in areas where these viruses also 
encounter increasing incidence and it is considered that up to 90% of the diagnosed HCCs 
develop in context of hidden cirrhosis [1, 2]. Other risk factors that are highly involved in 
the hepatocellular carcinogenesis also include autoimmune hepatitis, nonalcoholic fatty liver 
disease (NAFLD), obesity and diabetes, tobacco and alcohol abuse, environmental toxins, and 
iron overload.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2.1. Cirrhosis
Cirrhosis is the main underlying cause for most HCC cases, with HBV, and HCV infection 
often involved in the development of cirrhosis. Approximately 70–90% of liver cancers occur 
on cirrhosis, and in Western countries, the HCC ratio on cirrhosis exceeds 90%. The likelihood 
of developing HCC in viral B cirrhosis is 2.4% per year, and viral C cirrhosis is 5–7% per year. 
In Europe, HCC incidence is 1.5–3/100 cirrhosis per year. Male gender, advanced age, long 
duration of the disease and the severity of the disease are the main risk factors for developing 
cancer in cirrhosis alongside etiology of cirrhosis [3].
The progression from cirrhosis to HCC is a complex process. Cirrhosis is the outcome of any 
chronic hepatic illness and it is outlined by debilitation of regenerative capacity of the liver 
through declining proliferation of the hepatocytes [4]. Telomere dysfunction and alterations 
of cellular micro- and macroenvironment have been proven to enhance cellular proliferation 
[5]. Telomerase dysfunctions determine chromosomal instability and reduced regenerative 
liver capacity with decreased hepatocyte regeneration. It has been proven that telomeres are 
shorter in hepatocytes from a cirrhotic liver compared to a normal liver. Also, shorter telo-
meres are associated with the progression of liver fibrosis [6].
Several mouse models studies have suggested that telomerase dysfunctions have been associ-
ated with early-stage liver cancers but not with high-grade HCCs, which tends to indicate 
that telomere dysfunction cannot determine alone the development and progression of HCC 
in cirrhotic livers [7]. Van Gijssel et al. supported this idea by using a rat model in which they 
decreased hepatocyte proliferation with various hepatotoxic compounds that also increased 
carcinogen-induced tumor forming [8]. Activation of stellate cells in liver cirrhosis can increase 
products of oxidative stress, several growth factors as well as cytokines with further roles 
in reducing hepatocyte regeneration, and development of HCC [9]. Outbreaks of dysplasia 
occur in regeneration nodules, followed by neoplastic transformation. HCC rarely develops 
on the noncytotoxic liver and this is particularly common in HBV infection, hemochromatosis 
or HCV infection. The existence of viral infection or portal hypertension can increase the odds 
of developing HCC for patients with primary biliary cirrhosis [10].
2.2. HBV infection
HBV is regarded as the main etiological factor that generates multiple pathological changes 
inside the liver structure, being responsible for the development of HCC over time [11]. 
However, in order to correctly assess the risk of carcinogenesis triggered by chronic HBV 
infection, multiple variables need to be considered, like a virus or host-related factors and 
also the patient’s lifestyle [12]. A major study published Chen CJ et al. evaluated the risk of 
developing HCC in 3653 patients who were positive HBV infection and negative for hepatitis 
C antibodies. The authors concluded that recorded serum levels of HBV DNA higher or equal 
to 10,000 copies/mL are a significant risk predictor for the development of HCC, no matter the 
Hepatitis B antigen level and liver cirrhosis [13].
In highly endemic regions, HBV is mainly transmitted from mother to child during birth 
(perinatal exposure). In developed countries, HBV infection is primarily contracted through 
parental contact with infected blood or through sexual contact [14]. Co-infection with HBV 
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is found in 9% HIV-infected patients, resulting in an increased risk of developing HCC com-
pared to chronic HBV infection alone [15]. At the time of writing, there are 10 genotypes of 
human HBV named from A to J. The last genotype (J) was described in 2009 by Tatematsu K 
et al. [16], while the highest risk of developing HCC is linked with genotype C [17].
The prevalence of HBV carriers associates geographically with the distribution of HCC. 
Epidemiological studies indicated a 200-fold increase in HCC risk in Taiwanese HVB men 
compared to HBV-negative men [18]. Cirrhosis developed from chronic HBV infection is 
globally the most important etiologic factor of HCC.
Hepatocarcinogenesis generated by chronic HBV infection is a multistep process that implies 
rearrangement of the intracellular DNA leading to inflammation of the hepatocytes, accom-
panied by an increased rate of proliferation [19]. After the integration of viral DNA into the 
host’s genome, the telomerase reverse transcriptase is altered and multiple genes involved in 
the malignant process suffer various insertional mutations [20]. If the inflammation process 
continues to affect the hepatocytes, the liver will respond to injury with necrosis of the affected 
areas, followed by compensatory regeneration and hepatic fibrosis, therefore, altering the 
entire hepatic architecture, leading to cirrhosis [21]. Recent studies enhance the importance of 
HBV X protein, suggesting that pathways like p38MAPK and PI-3 K/AKT are used in order 
to increase the invasive potential of HBV infection [22, 23]. The association of HBV infection 
with HCV or HVD or with increased alcohol intake or aflatoxin consumption increases the 
carcinogenic risk of HBV [24].
2.3. HCV infection
Chronic hepatitis C infection is a major risk factor for developing HCC. In developed coun-
tries, HCV is the important risk factor for HCC. HCV-associated HCC patients are usually 
significantly older than those with HCC associated with HBV infection [16].
The evolution over time of the viral infection in a few countries is pledged for the massive 
increase of HCC incidence. The major spread of HCV infection took place in Japan around 
the 1930s and in the US in the 1960s. These assessments are consistent with epidemiological 
observations and allow the estimate that HCC prevalence will increase in the US over the next 
2–3 decades when it is likely to match that in Japan [25]. HBV co-infection, present in 3–13% 
of patients with viral hepatitis C, is associated with a HCC risk of 3–4 times the incidence of 
each infection [26]. It is considered that the survivors of the Hiroshima and Nagasaki nuclear 
bombs that were HCV-positive had a much higher risk of developing HCC in the absence of 
cirrhosis. It was suggested that the radiation had a mutagenic effect and C virus stimulated 
cell proliferation in these patients [27]. Almost all HCV-related hepatocarcinomas occur due 
to cirrhosis or chronic inflammation. It is therefore, believed that HCV is an indirect carcino-
genic agent by induced inflammatory and necrotic lesions. Core protein influences various 
cellular functions, including apoptosis, and suppresses p53 activity [28–30].
2.4. Autoimmune hepatitis
The risk of developing HCC for patients with underlying autoimmune hepatitis still remains 
unclear. Development of HCC in the absence of cirrhosis or viral hepatitis is rather rare or 
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isolated [31]. A recent meta-analysis concluded that the risk of HCC is much lower for patients 
with autoimmune hepatitis and cirrhosis than for patients with cirrhosis from viral hepatitis 
or primary biliary cholangitis [32, 33]. Development of HCC from autoimmune hepatitis with 
corticosteroid-therapy should mainly impose searching for associated viral chronic hepatitis 
or any other HCC risk factors that can promote carcinogenesis [34].
2.5. Tobacco and alcohol abuse
Tobacco and alcohol abuse represent important HCC risk factors and exposure to both risk 
factors can increase HCC susceptibility. The mechanism involves generation of reactive oxy-
gen species (ROS) and a decrease of antioxidants, which induces oxidative stress [35].
Alcohol chronic intake is associated with HCC development due to the several mechanisms 
such as creation of acetaldehyde-DNA; formation of cytochrome P450E1-associated ROS 
species; iron overload, which can lead to further ROS formation and p53 gene mutation or 
activation of factor-KappaB-involved in the promotion of inflammatory response; oxidative 
stress promotion; and decreased metabolism of vitamin A, which determines the promotion 
of hepatocyte proliferation as well as initiation and development of liver fibrosis [36]. Alcohol 
interferes with hepatocarcinogenesis by inducing an already demonstrated precancerous 
lesion, such as liver cirrhosis or by modifying carcinogenesis initiated by other agents such 
as HBV or HCV or environmental carcinogens following hepatic enzyme induction or by 
altering cell membranes [37].
2.6. Environmental toxins
Aflatoxin b1 derived from a fungus (Aspergillus flavus) is a major risk factor in some tropi-
cal and subtropical regions. Aspergillus flavus is ubiquitous and contaminates cereals (corn, 
rice, and sorghum), hazelnuts, etc., stored in humidity conditions. Epidemiological data have 
shown a strong correlation between aflatoxin intake and HCC incidence in some countries 
in Asia and Africa. Since 1993, the International Agency for Research on Cancer recognized 
aflatoxins as a human carcinogen (group IA) [38]. Advanced age, smoking, alcohol, and HBV 
infection may increase the carcinogenic risk of aflatoxin [39].
2.7. Obesity, diabetes and nonalcoholic fatty liver disease (NAFLD)
Obesity represents an important public health problem, with a massive increase in the past 
years and with staggering estimations of approximately 300 million obese worldwide. Obesity 
elevates the risk of all types of cancer, including HCC [40]. One study performed in Denmark 
on a cohort of 43.965 obese patients estimated the relative risk of liver cancer to 1.9 in com-
parison to the general population [41]. Two Swedish population-based cohort studies also 
showed an increased risk of HCC among obese [42, 43].
In another US study, Nair et al. evaluated the importance of obesity in over 19,000 patients 
diagnosed with cirrhosis and liver transplants, with an overall incidence for HCC of 3.5%. The 
study suggested obesity as a statistically independent risk factor for liver cancer in patients 
with alcoholic and cryptogenic cirrhosis [44]. Furthermore, a recent case–control study 
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indicated synergy between increased alcohol intake, smoking, and obesity [45]. In 2014, an 
American study regarding the incidence of hepatocellular carcinoma in Texas Latinos con-
cluded that the incidence of liver cancer is somehow higher than other regions in the US, sug-
gesting risk factors related to increased obesity and diabetes rates, as well as environmental, 
cultural and socioeconomic factors, and possibly genetic predisposition [46].
The mechanism by which obesity leads to cancer is unclear; insulin resistance and its subse-
quent inflammatory cascade, and insulin growth factor (IGF)-1 seem to be implicated [47]. In 
a study published in 2010, Michael Karin’s team addressed the mechanism by which the obe-
sity can lead to cancer by studying the development of HCC induced by diethylnitrosamine 
(DEN) or fat diet in mice [48, 49].
Although this is not entirely proven, a number of studies indicate that NAFLD is the link 
between obesity, diabetes, and HCC. In time, NAFLD can lead to fibrosis and finally, cirrho-
sis. Approximately 60% of patients with obesity have simple steatosis or steatosis with mild 
inflammation and around 25–30% have nonalcoholic steatohepatitis (NASH) [50].
Further mechanisms involved in the development of HCC at obese patients were addressed 
by Villanueva et al. by studying the molecular links between inflammation and liver cancer 
uncovering the reported role of lymphotoxin signaling in HCC development. The involve-
ment of oxidative stress in developing HCC in obese patients was studied by Zhang, Kaufman 
et al., who underlined that the accumulation of intracellular lipids increases the demand on 
the endoplasmic reticulum (ER), which integrates several metabolic processes, therefore 
inducing ER dysfunction that leads to the production of ROS, provoking oxidative stress and 
activation of inflammatory pathways (NF-kB and JNK signaling). Another effect of oxidative 
stress is that can also induce DNA damage that leads to genomic instability that prompts the 
mutations that favor the development of neoplastic cells [51–53]. Carbohydrate metabolism 
alterations are frequently encountered at patients with cirrhosis [54].
Since 1986 at least 10 case-control and 5 prior cohort studies from seven different countries 
reported a connection between diabetes and HCC, promoting the idea that diabetes is an 
important and consistent risk factor for HCC [55–57]. However, the current studies have not 
established if diabetes precedes HCC.
The association among obesity, diabetes, NAFLD, and HCC has been assessed by El-Serag 
et al. in two large studies that substantiated the increased risk of HCC by obtaining results, 
which showed a doubling number of cases with HCC in patients with diabetes in contrast 
with nondiabetic patients in a 10–15 year observation period, explaining that the rising inci-
dence of HCC in the US in the past 30 years is connected to an ever-growing prevalence of 
obesity and diabetes [58, 59].
Since the incidence of obesity and diabetes is in a continuous growth in the world, Kelly, and 
co. study demonstrated a direct established relationship between diabetes and HCC risk. The 
biological mechanism of diabetes implicated in hepatocarcinogenesis is not entirely estab-
lished. Increased serum levels of insulin are at this point the most researched mechanism for 
the link between diabetes and cancer, though only high levels of insulin are not enough to 
cause HCC. Levels of insulin-like growth factor-1 (IGF-1) have been linked with increased 
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risk for pancreatic cancer [60–62]. Most studies indicate that serum IGF-1 levels were linked 
with the high-risk of HCC, and also that IGF-1 can promote tumor cell growth [63–66]. This 
was often linked to cell proliferation in pancreatic cancer and similar effects could be observed 
in HCC [62, 67].
As diabetes and obesity continue to be an ever-growing worldwide concern, we can anticipate 
a near future increase in the prevalence of NAFLD-related HCC [68]. If liver cirrhosis is pres-
ent, NAFLD patients have a substantially higher risk to develop HCC [69]. Obesity is linked 
with a low-grade inflammatory status and also an increased production of cytokines like IL-6 
or TNF-alpha [70]. Multiple potential carcinogenic mechanisms are also involved, such as 
reduced levels of adiponectin [71, 72], hepatic lipid accumulation with possible energy sup-
port required for massive tumor growth [73] or normal intracellular signaling means affected 
by lipotoxicity [74].
2.8. Iron overload
Almost two thirds of the total iron pool is present in hemoglobin while the rest of it is stored, 
mostly inside the liver, with the help of an intracellular protein called ferritin, which can bind 
up to 4500 molecules of iron per molecule of ferritin. Transferrin is a glycoprotein responsible 
for binding the circulating iron within the plasma [75]. Iron overload has been mainly associ-
ated with hereditary hemochromatosis (HH) and dietary iron overload (DIO).
Iron overload is frequently linked with an abnormal secretion of hepcidin [76, 77]. Recent 
studies performed on rats, which underwent a high-iron diet also confirm the possibility to 
develop HCC in the absence of liver cirrhosis, therefore, excessive iron is capable to generate 
oxidative tissue damage alone by accelerating the development of free radicals [78, 79]. DIO 
has been reported in some countries located in the southern and central part of Africa, mainly 
in the rural parts and highlights the link between the consumption of large volumes of home-
brewed alcohol using iron containers, and development of iron overload [79].
3. Conclusion
HCC is a complex pathogenesis link with various risk factors. Liver cirrhosis is, unsurpris-
ingly, an important risk factor for HCC development, regardless of the cause, whereas 
chronic HBV and HCV infections are the most significant developing factors for liver cancer 
worldwide. Therefore, frequent causes of cirrhosis are indicated as risk factors for HCC. The 
common factors affecting the progression to HCC in patients with cirrhosis are host and viral 
related with the involvement of external risk factors such as smoking, alcohol, and aflatoxins.
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